



MIVI Neuroscience Announces First-In-Man Series of The DAISe Clot Management System

EDEN PRAIRIE, Minn., June 29, 2018 /PRNewswire/ -- MIVI Neuroscience, Inc. announced today it has successfully achieved first-in-man usage of the DAISe Clot Management System for next generation treatment of ischemic stroke.

The proprietary DAISe Clot Management System is uniquely designed to remove clot as well as filter / capture clot emboli that fracture during removal. DAISe features a three-dimensional meshwork of hundreds of polymeric fibers to capture debris as small as 40 um while allowing blood flow to be maintained through the device.

The DAISe Clot Management System's first in man usage occurred in South America. MIVI plans to pursue additional clinical trials based on the encouraging outcomes of this series, as well as previous in vivo and animal studies.

"We are very excited about this first-in-man usage of the DAISe Clot Management System. This is obviously a major milestone for our company," said Jim McCollum, MIVI's CEO. "We believe the DAISe – as well as our entire suite of devices - offers unique features and benefits not realized today in ischemic stroke treatment. We look forward to developing the DAISe device and ultimately delivering it to the worldwide neurovascular community to help improve patient outcomes, and more specifically, not just achieving short term patency by removing clot, but ultimately improving a stroke patient's functional outcomes by managing or even eliminating distal embolic fragments."

About MIVI Neuroscience

MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Adoption of endovascular stroke therapy procedures is growing significantly worldwide since compelling data from multiple large-scale randomized trials in 2016 and 2017 confirmed the value to rapidly clear occlusive clot from large cerebral vessels. MIVI's innovative product portfolio provides physicians with unique devices designed to improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients. More information about MIVI can be found on the

MIVI Neuroscience, Inc.

6545 City West Parkway • Eden Prairie, MN 55344 • (952)944-3834

www.mivineuro.com